Animal Tissue Cell Culture Patents (Class 435/70.3)
-
Publication number: 20110293667Abstract: Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be produced with multiple cell types that can all contribute to producing the extracellular matrix. Additionally or alternatively, one of the multiple cell types can be delivered to a site in the body via the endogenously produced extracellular matrix components to achieve various therapeutic benefits.Type: ApplicationFiled: January 14, 2011Publication date: December 1, 2011Inventors: Dolores Baksh, Xianyan Wang, Matthew Q. Wong, Lan Cao, Parid Sava, Thomas Bollenbach, Esin Yesilalan
-
Publication number: 20110287071Abstract: A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.Type: ApplicationFiled: January 31, 2010Publication date: November 24, 2011Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventor: Eduardo N. Mitrani
-
Publication number: 20110287482Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.Type: ApplicationFiled: August 4, 2011Publication date: November 24, 2011Applicant: Baxter Innovations GmbHInventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner, Leopold Grillberger, Artur Mitterer
-
Publication number: 20110280914Abstract: Described herein are composites useful in tissue and organ engineering. In one aspect, the composite comprises the reaction product between a macromolecule comprising at least one thiol group and a gold nanoparticle. The thiolated macro-molecule crosslinks with the gold nanoparticle to produce a composite that is useful in anchoring cells. The composites can be used to form multi-layer 3-D structures, where the cells in each layer can aggregate and fuse with one another to form tissues and organs.Type: ApplicationFiled: December 17, 2009Publication date: November 17, 2011Applicant: University of Utah Research FoundationInventors: Glenn D. Prestwich, Aleksander Skardel, Jianxing Zhang
-
Publication number: 20110275539Abstract: The invention relates to a method and to a substrate for selecting and specifically influencing the function of cells by the adhesion thereof to substrate surfaces having prescribed properties. Said substrates comprise various surface regions each representing a condition affecting the cell adhesion and/or cell function, and said conditions are determined by a geometric property and/or a mechanical property or a combination of a geometric property and/or a mechanical property with a chemical property of each surface region. The invention further relates to analysis devices and to analysis methods using said substrates for identifying and selecting particular cell types, for identifying suitable substrate conditions for affecting a particular cell function or particular cell type or for identifying disease states characterized by a change in the cell type or cell function.Type: ApplicationFiled: December 7, 2009Publication date: November 10, 2011Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Joachim P. Spatz, Nadine Perschmann, Ann-Kathrin Wandner, Roberto Fiammengo
-
Patent number: 8053236Abstract: The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods.Type: GrantFiled: May 9, 2008Date of Patent: November 8, 2011Assignee: Amgen Inc.Inventors: Arvia Eleanor Morris, Aurora Villegas Viaje, Erika Pineda
-
Publication number: 20110262392Abstract: The invention provides an apoptosis-modulating cell-free composition comprising conditioned extracellular medium of a stem cell and uses thereof, particularly therapeutic uses. Also provided is a method of obtaining such a composition and an in vitro method of modulating apoptosis.Type: ApplicationFiled: October 2, 2009Publication date: October 27, 2011Applicant: OMNICYTE LIMITEDInventors: Nagy A. Habib, Myrtle Gordon
-
Publication number: 20110250644Abstract: An improved feed supplement for culture of mammalian cells used to produce proteins is provided. The improved supplement is devoid of animal-derived components and protein hydrolysates. The invention also provides methods of using the supplement in production of a therapeutic proteins, such as an antibody. In some embodiments, the antibody is an anti-human IL-23p19 antibody.Type: ApplicationFiled: December 17, 2009Publication date: October 13, 2011Applicant: Schering CorporationInventors: Wai Lam W. Ling, Anli Ouyang, Matthew S. Manahan
-
Publication number: 20110250624Abstract: The subject of the present invention is a method of obtaining purified BLV gp51 antigen as well as a novel ELISA assay using said antigen. The present invention is useful in the diagnosis of enzootic leukaemia in cattle.Type: ApplicationFiled: September 27, 2009Publication date: October 13, 2011Inventors: Andrzej Rapak, Ewn Ziolo
-
Publication number: 20110250236Abstract: Adult stem cells obtained from the carotid body, characterized in that they are positive for the phenotypic marker GFAP (glial fibrillary acidic protein) and negative for the phenotypic markers TH (tyrosine hydroxylase) and nestin, are described. These stem cells can undergo proliferation, self-renewal and differentiation to progenitor cells and differentiated cells. Said stem cells, progenitor cells and differentiated cells, expanded by any method, can be used in the treatment of neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease.Type: ApplicationFiled: August 1, 2008Publication date: October 13, 2011Applicant: UNIVERSIDAD DE SEVILLAInventors: Jose Lopez Barneo, Ricardo Pardal, Patricia Ortega-Saenz, Rocio Duran, Victoria Eugenia Bonilla Henao, Antonio Ordonez Fernandez, Juan Jose Toledo Aral
-
Patent number: 8030026Abstract: The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.Type: GrantFiled: February 24, 2009Date of Patent: October 4, 2011Assignee: Abbott LaboratoriesInventors: Susan E. Brophy, Bailin Tu, Joan D. Tyner, Lowell J. Tyner, legal representative, Dagang Huang, Robert N. Ziemann
-
Patent number: 8029778Abstract: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or 4, specifically binds to the mammalian Toll-like receptor 3 and induces production of type I interferon. A mutant of the adaptor protein TICAM-1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4). The gene is a gene encoding the adaptor protein TICAM-1.Type: GrantFiled: March 31, 2009Date of Patent: October 4, 2011Assignee: Japan Science and Technology AgencyInventors: Tsukasa Seya, Misako Matsumoto, Hiroyuki Oshiumi
-
Publication number: 20110217318Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.Type: ApplicationFiled: April 27, 2011Publication date: September 8, 2011Inventors: HIROSHI TAKAYAMA, KAMON SHIRAKAWA, SHOJI FURUSAKO, YOSHITAKA HOSAKA, TOMOKAZU MATSUSUE, KATSUKI NAITOH, YUMI HOTTA, TETSUSHI KAWAHARA, MOTOYASU HONDA
-
Publication number: 20110212894Abstract: Methods for fabricating a tissue-engineered construct comprising: providing a tissue-engineered construct, wherein the tissue-engineered construct is derived from a xenogenic source; and decellularizing the tissue-engineered construct.Type: ApplicationFiled: February 17, 2011Publication date: September 1, 2011Inventors: Kyriacos A. Athanasiou, Benjamin Daniel Elder
-
Publication number: 20110207171Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.Type: ApplicationFiled: January 14, 2011Publication date: August 25, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Brian Agnew, Schuyler B. CORRY, Kyle R. GEE
-
Publication number: 20110207175Abstract: There is provided co-culture bioreactor systems that can maintain stem cells and differentiated cell types in physically isolated environments but can allow biochemical communication between these cells. For instance, a co-culture bioreactor system of the present invention can include a first culture chamber that defines a first inlet and a first outlet such that fluid can flow through the culture chamber. The system can also include a second culture chamber defining a second inlet and a second outlet allowing a second fluid flow through this second chamber. The system can also include a semi-permeable membrane. The semi-permeable membrane can be located between the first culture chamber and the second culture chamber.Type: ApplicationFiled: October 2, 2009Publication date: August 25, 2011Applicant: MC2 Cell ApSInventors: Marwan El-Sabban, Steen Sindet-Pedersen
-
Publication number: 20110203009Abstract: It is an object of the present invention to investigate what kinds of structures a sugar chain has by performing a sugar chain structural analysis of a glycoprotein produced in a transgenic silkworm. For the sugar chain of the glycoprotein produced in the transgenic silkworm, a glycoprotein having a sugar chain structure in which fucose is not linked to N-acetylglucosamine at a reducing terminal of the sugar chain is obtained. In addition, a glycoprotein having an almost completely humanized sugar chain structure is obtained by further integrating GalT gene into this transgenic silkworm.Type: ApplicationFiled: June 15, 2009Publication date: August 18, 2011Inventors: Masahiro Tomita, Shinichi Nakakita, Jun Hirabayashi
-
Publication number: 20110177132Abstract: The present disclosure provides compositions comprising musculoskeletal cells and mesenchymal stem cells in discrete regions. The present disclosure provides systems comprising a subject composition; and methods of using a subject composition to generate cartilage, bone, tendon, muscle, intervertebral disc, or other musculoskeletal tissues.Type: ApplicationFiled: May 22, 2009Publication date: July 21, 2011Inventors: Aliza Apple Allon, Jeffrey Charles Lotz, Richard Alan Schneider
-
Publication number: 20110151005Abstract: Cellfree adipose tissue extracts, implants including the same and methods for the preparation thereof. The extracts and implants are capable of inducing adipogenesis and angiogenesis and are, thus, useful in applications including soft tissue repair and engineering and angiogenesis induction, e.g., in wound healing, treatment of burn injuries and ischemic conditions.Type: ApplicationFiled: March 4, 2011Publication date: June 23, 2011Inventors: Timo YLIKOMI, Jertta-Riina Sarkanen
-
Publication number: 20110143397Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.Type: ApplicationFiled: December 7, 2010Publication date: June 16, 2011Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
-
Publication number: 20110123539Abstract: A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 151P3D4 can be used in active or passive immunization.Type: ApplicationFiled: January 28, 2011Publication date: May 26, 2011Applicant: AGENSYS, INC.Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
-
Publication number: 20110117603Abstract: Disclosed herein are methods of modulating protein production via the application of tensegrity forces on cells and cell cultures. The methods of the invention increase production of protein from cells and cell culture. The tensegrity forces can be stress that is applied to the cells, and can include one or more of the following: mechanical stress, shear stress, stretch effects, and pressure induced stress.Type: ApplicationFiled: July 15, 2010Publication date: May 19, 2011Applicant: Abbott LaboratoriesInventors: Reema Piparia, Ivan Correia
-
Publication number: 20110110956Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.Type: ApplicationFiled: September 26, 2008Publication date: May 12, 2011Applicants: AMGEN, INC., U3 PHARMA GMBHInventors: Mike Rothe, Norbert Prenzel, Eric Borges, Thore Hettmann, Esther Zwick-Wallasch, Orit Foord
-
Publication number: 20110097336Abstract: The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins.Type: ApplicationFiled: September 29, 2009Publication date: April 28, 2011Applicant: AMGEN INC.Inventors: Jian WU, Nicole LE, Michael DE LA CRUZ, Gregory FLYNN
-
Publication number: 20110081682Abstract: The present disclosure provides methods for producing Bone Morphogenetic Proteins (BMPs). The BMPs are produced using ex vivo-derived mineralized three-dimensional bone constructs of varying degrees of maturity and mineralization. The bone constructs are obtained by culturing osteoblasts and osteoclast precursors under randomized gravity vector conditions whereupon the bone constructs secrete BMPs into the culture medium. Culture medium is periodically removed from the bone construct culture, and the BMPs are purified from the removed culture medium.Type: ApplicationFiled: November 13, 2008Publication date: April 7, 2011Applicant: OSTEOSPHERE, LLCInventors: Mark Brinker, Mark S.F. Clarke, Alamelu Sundaresan
-
Publication number: 20110081679Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise the addition of glucocorticoid compound during the culturing period. The addition of glucocorticoid compound sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e.g., by sialic acid content of the produced protein.Type: ApplicationFiled: October 5, 2010Publication date: April 7, 2011Inventors: Ying Jing, Zhengjian Li, Yueming Qian
-
Patent number: 7910320Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.Type: GrantFiled: August 13, 2008Date of Patent: March 22, 2011Assignee: Galapagos N.V.Inventors: Pascal Gerard Merchiers, Marcel Hoffman, Koenraad Frederik Florentina Spittaels
-
Publication number: 20110065142Abstract: Adipose cells (sebocytes) are described, The invention especially relates to sebaceous gland cells and to a sebaceous gland cell line with the property of being continuously grown over many sub-cultures. The sebocytes are excellently suited for useful applications.Type: ApplicationFiled: October 1, 2008Publication date: March 17, 2011Inventor: Christos Zouboulis
-
Publication number: 20110053855Abstract: Provided herein is are methods for evaluating the biological activity and/or therapeutic potential of a glucan, comprising in one embodiment: co-culturing a first population of cells with a second population of cells, wherein the first population comprises cells capable of being stimulated by said glucan to produce and/or secrete cytokines and growth factors, and the second population comprises collagen-producing cells; contacting said co-cultured cells with the glucan and incubating for a period of time sufficient to induce the production of collagen from the collagen-producing cells; and determining the level of production of collagen from said collagen-producing cells, wherein the level of production of collagen is indicative of the biological activity and/or therapeutic potential of the glucan.Type: ApplicationFiled: February 19, 2009Publication date: March 3, 2011Inventor: Reinhard Koenig
-
Publication number: 20110045535Abstract: It is intended to provide an activator for blood coagulation factor VII. Ribavirin or its derivative is used as an activator for blood coagulation factor VII promoter.Type: ApplicationFiled: August 27, 2008Publication date: February 24, 2011Applicant: National University Corporation Nagoya UniversityInventors: Takashi Honda, Junki Takamatsu, Hidenori Toyoda, Koji Yamamoto, Hidemi Goto, Tetsuhito Kojima
-
Patent number: 7871819Abstract: The invention provides a recombinant vector comprising an ovine adenovirus genome and a sequence encoding a heterologous polypeptide, wherein the sequence encoding the heterologous polypeptide is inserted between E4 and E3 transcription units of the ovine adenovirus genome.Type: GrantFiled: December 20, 2005Date of Patent: January 18, 2011Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Peter L. Molloy, Fujiko Watt, Gerry Both
-
Patent number: 7867731Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.Type: GrantFiled: October 28, 2004Date of Patent: January 11, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Christoph Reinhard, Anne Bennett Jefferson, Vivien W. Chan, Joerg Kaufmann, Hong Xin, Giulia C. Kennedy, Greg Harrowe, Hamiduddin Khoja, Venkatakrishna Shyamala
-
Patent number: 7858346Abstract: The present invention provides a medicine, comprising (a) an Otx2 protein or its partial peptide, or a salt thereof, or (b) a DNA or an RNA encoding an Otx2 protein or its partial peptide. The present medicine is useful as an agent for preventing, treating or suppressing progression of a retinal disease including retinal degeneration. In addition, the present medicine is useful, for example, as an agent for inducing differentiation from a retinal stem cell into a retinal photoreceptor cell, in the transplantation of a cell into the retina of patients suffering from retinal diseases.Type: GrantFiled: February 2, 2004Date of Patent: December 28, 2010Assignee: Japan Science Technology AgencyInventor: Takahisa Furukawa
-
Patent number: 7833753Abstract: Disclosed are immortalized human embryonic retina cells, having a nucleic acid sequence encoding an adenoviral E1A protein integrated into the genome of the cells, and further comprising a nucleic acid sequence encoding an enzyme involved in post-translational modification of proteins, such as a sialyltransferase, wherein the nucleic acid sequence encoding the enzyme involved in post-translational modification of proteins is under control of a heterologous promoter. Methods for producing recombinant proteins from such cells and obtaining such recombinant proteins having increased sialylation are provided as are novel compositions of isoforms of erythropoietin.Type: GrantFiled: June 20, 2007Date of Patent: November 16, 2010Assignee: Crucell Holland B.V.Inventors: Dirk J. E. Opstelten, Alphonsus G. C. M. UytdeHaag
-
Patent number: 7807417Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.Type: GrantFiled: February 22, 2007Date of Patent: October 5, 2010Assignee: Intrexon CorporationInventors: Subba Reddy Palli, Marianna Zinovjevna Kapitskaya, Dean Ervin Cress
-
Patent number: 7794928Abstract: A norovirus-permissive cell culture infected with a norovirus, and methods of culturing a norovirus, are disclosed. Norovirus-permissive cells include dendritic cell-lineage cells, and macrophage-lineage cells, such as dendritic cells, and macrophages having a deficiency in a cellular anti-viral pathway such as a STAT-1-dependent pathway, an interferon receptor-dependent pathway, or a PKR-dependent pathway. Also disclosed are methods of screening anti-viral compounds against norovirus-permissive cells infected with norovirus, and norovirus adapted to grow in fibroblasts as well as macrophages that are not deficient in a cellular anti-viral pathway. Methods of making a norovirus vaccine are also disclosed. A replicative form of norovirus as well as its use in the development of an anti-viral agent and a polypeptide expression system are also described. Further disclosed are methods of detecting norovirus in a sample.Type: GrantFiled: February 4, 2008Date of Patent: September 14, 2010Assignee: Washington UniversityInventors: Herbert W. Virgin, Christiane Wobus, Stephanie Karst
-
Patent number: 7781158Abstract: A method for separation the collagen from the various animal tissues is disclosed for preparing collagen solution and product using the same. The porcine tissues are processed to have proper form and size for acid-treatment. The acid-treatment is repeated with pepsin to separate type I or II collagens. The separated collagen is salt-treated for fractionation and ethanol-treated for obtaining 5˜10% of collagen from the initial tissue weight. The prepared tissues are processed for separating collagen through the collagen separating process. The separated collagen is processed for preparing product. The method for preparing product is comprised: treating a collagen solution having a predetermined concentration under a neutral condition at a low temperature, followed by overnight treatment at a temperature of 30 to 35° C.Type: GrantFiled: March 9, 2006Date of Patent: August 24, 2010Assignee: SEWON CELLONTECH Co., Ltd.Inventors: Ji-Chul Yu, Jae-Deog Jang, Cheong-Ho Chang, Sae-Bom Lee, Se-Geun Yeo, Chang-Kwon Ko
-
Publication number: 20100210530Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.Type: ApplicationFiled: December 7, 2009Publication date: August 19, 2010Applicant: Histogen, Inc.Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
-
Publication number: 20100203135Abstract: Methods of forming soft connective tissue compositions such as skin equivalents, compositions made by the methods and their uses.Type: ApplicationFiled: March 14, 2006Publication date: August 12, 2010Inventors: Paul Kemp, David Shering, Andrew Shering, Penny Johnson, Damian Marshall
-
Publication number: 20100196963Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.Type: ApplicationFiled: August 25, 2009Publication date: August 5, 2010Applicant: Histogen, Inc.Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
-
Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
Patent number: 7767786Abstract: The invention discloses a family of neuronal migration-inducing, proliferation-promoting and neurite outgrowth promoting factors, termed NRP compounds, and provides compositions and methods for the use of NRP compounds in the treatment of brain injury and neurodegenerative disease. NRP compounds induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient.Type: GrantFiled: August 22, 2002Date of Patent: August 3, 2010Assignee: Neuren Pharmaceuticals Ltd.Inventors: Frank Sieg, Paul Hughes -
Publication number: 20100184148Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: ApplicationFiled: February 17, 2010Publication date: July 22, 2010Applicant: VAXDESIGN CORPORATIONInventors: Selva SUKUMAR, Mohey Eldin M. EL SHIKH, John G. TEW, Guzman SANCHEZ-SCHMITZ, Donald DRAKE, III, Luis MOSQUERA, Eric MISHKIN, Anatoly M. KACHURIN, Russell HIGBEE, Conan LI, William L. WARREN, Heather FAHLENKAMP
-
Patent number: 7749733Abstract: The invention is concerned with the systematic elucidation and identification of regulatory sequences. The invention provides among others screenings and detection methods with which regulatory sequences can be identified. The invention further provides regulatory sequences and use thereof in various fields such as, but not limited to, protein production, diagnostics, transgenic plants and animals, and the therapeutic field.Type: GrantFiled: October 13, 2006Date of Patent: July 6, 2010Assignee: Chromagenics B.V.Inventors: Arie P. Otte, Arthur L. Kruckeberg
-
Patent number: 7741079Abstract: A method of making a genetically modified mammalian cell, the method including selecting a first codon of a parent polynucleotide that encodes a polypeptide for replacement with a synonymous codon, wherein the synonymous codon is selected on the basis that it exhibits a higher translational efficiency in a first type of mammalian cell than the first codon in a comparison of translational efficiencies of codons in cells of the first type, replacing the first codon with the synonymous codon to form a synthetic polynucleotide, and introducing the synthetic polynucleotide into a mammalian cell to produce the genetically modified mammalian cell.Type: GrantFiled: November 2, 2006Date of Patent: June 22, 2010Assignee: University of the QueenslandInventors: Ian Hector Frazer, Jian Zhou, Xiao Yi Sun, legal representative
-
Patent number: 7736868Abstract: The invention is concerned with the systematic elucidation and identification of regulatory sequences. The invention provides among others screenings and detection methods with which regulatory sequences can be identified. The invention further provides regulatory sequences and use thereof in various fields such as, but not limited to, protein production, diagnostics, transgenic plants and animals, and the therapeutic field.Type: GrantFiled: October 13, 2006Date of Patent: June 15, 2010Assignee: Chromagenics B.V.Inventors: Arie P. Otte, Arthur L. Kruckeberg
-
Patent number: 7736870Abstract: The invention is concerned with the systematic elucidation and identification of regulatory sequences. The invention provides among others screenings and detection methods with which regulatory sequences can be identified. The invention further provides regulatory sequences and use thereof in various fields such as, but not limited to, protein production, diagnostics, transgenic plants and animals, and the therapeutic field.Type: GrantFiled: October 13, 2006Date of Patent: June 15, 2010Assignee: Chromagenics B.V.Inventors: Arie P. Otte, Arthur L. Kruckeberg
-
Patent number: 7736869Abstract: The invention is concerned with the systematic elucidation and identification of regulatory sequences. The invention provides among others screenings and detection methods with which regulatory sequences can be identified. The invention further provides regulatory sequences and use thereof in various fields such as, but not limited to, protein production, diagnostics, transgenic plants and animals, and the therapeutic field.Type: GrantFiled: October 13, 2006Date of Patent: June 15, 2010Assignee: Chromagenics B.V.Inventors: Arie P. Otte, Arthur L. Kruckeberg
-
Publication number: 20100120093Abstract: The invention provides methods and compositions for the serum-free, insulin-free production of recombinant Factor VII.Type: ApplicationFiled: November 5, 2009Publication date: May 13, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Simone von Fircks, Ruth Elmer, Manfred Reiter
-
Patent number: 7709229Abstract: This invention relates to a process for the manufacturing of a protein in mammalian cells cultured in a serum-free medium.Type: GrantFiled: October 28, 2005Date of Patent: May 4, 2010Assignee: Ares Trading S.A.Inventors: José Casatorres Hernandez, Carlos Martin Piera
-
Publication number: 20100062477Abstract: The present invention describes benign tumor stem cells, a method of isolating the benign tumor stem cells, a method of generating the benign tumor stem cells and a method of using the benign tumor stem cells. Uses of the benign tumor stem cells, such as pituitary stem cells include but are not limited to producing pituitary hormones and identifying drugs to treat pituitary disease conditions or pituitary-related disease conditions.Type: ApplicationFiled: November 28, 2007Publication date: March 11, 2010Applicant: CEDARS-SINAI MEDICAL CENTERInventor: John S. Yu